Lexatumumab Antibody

SKU: orb1980628

Description

Lexatumumab (GHS-ETR2) is a human agonistic monoclonal antibody targeting TRAIL-R2 (DR5) to induce apoptosis in cancer cells. It is a research tool for studying malignant pleural mesothelioma (MPM), with demonstrated pro-apoptotic activity in both in vitro cell cultures and in vivo xenograft models.

Research Area

Cell Biology

Key Properties

• CAS Number: 845816-02-6
• MW: 143.48 kDa
• Purity: > 95%
• Target: Apoptosis

Bioactivity

• In Vivo:
  Lexatumumab ( 10mg / kg, intravenous injection, twice a week ) combined with Dacarbazine can increase the anti-tumor effect in mice [ 2 ].
• In Vitro:
  Combining lexatumumab with cisplatin can synergistically inhibit cell growth and enhance apoptosis and death. In different melanoma cell lines, lexatumumab (0-10 μg/ml, 72 h) induced varying degrees of cell death.

Storage & Handling

• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Apoptosis, DR5 mAB, Lexatumumab, HGS-ETR 2, ETR2-ST01, TRAIL

Quick Database Links

Gene Symbol

Apoptosis